Nearly 40 women detained at Delaney Hall join striking men and outline demands ‘rooted in basic human rights’ Dozens of women detained inside the Delaney Hall immigration detention facility in New Jersey announced their participation in a hunger and labor strike, advocates announced on Thursday. The women, detained in unit 1 of the contentious privately run facility, also released a new list of de...
Nearly 40 women detained at Delaney Hall join striking men and outline demands ‘rooted in basic human rights’ Dozens of women detained inside the Delaney Hall immigration detention facility in New Jersey announced their participation in a hunger and labor strike, advocates announced on Thursday. The women, detained in unit 1 of the contentious privately run facility, also released a new list of demands. They are calling on Immigration and Customs Enforcement (ICE) to release women under 21, women with medical conditions and mothers. They are also demanding improved conditions inside the facility and for their immigration cases to proceed more quickly. Continue reading...
Bloody mary, but not as you know it … This sour-spicy twist on the classic brunch drink is very easy to recreate at home. Heath Ball, owner, The Red Lion & Sun , London N6 Continue reading...
Bloody mary, but not as you know it … This sour-spicy twist on the classic brunch drink is very easy to recreate at home. Heath Ball, owner, The Red Lion & Sun , London N6 Continue reading...
Zhejiang University in China has overtaken Harvard University to become the top academic institution in the world, according to the 2026 Nature Index. This is the first time Harvard has lost its top position in the rankings since the index’s inception in 2014. Tsinghua University, also from China, was third. Chinese institutions dominated this year’s list, accounting for nine of the top 10 – up fr...
Zhejiang University in China has overtaken Harvard University to become the top academic institution in the world, according to the 2026 Nature Index. This is the first time Harvard has lost its top position in the rankings since the index’s inception in 2014. Tsinghua University, also from China, was third. Chinese institutions dominated this year’s list, accounting for nine of the top 10 – up from eight in last year’s rankings. Of the top 20, China has 17, with Stanford University No 12 and...
Canaccord Genuity managing director George Gianarikas joins Yahoo Finance to explain why power and energy constraints are an existential risk for the artificial intelligence (AI) data center build-out.
Canaccord Genuity managing director George Gianarikas joins Yahoo Finance to explain why power and energy constraints are an existential risk for the artificial intelligence (AI) data center build-out.
Discover how a disciplined mix of stocks, bonds, and an income cushion can support steady retirement withdrawals, reduce risk, and keep emotions out of portfolio decisions. Watch the video below to learn practical rules for rebalancing in retirement. *This video was published on May 29, 2026. Continue reading
Discover how a disciplined mix of stocks, bonds, and an income cushion can support steady retirement withdrawals, reduce risk, and keep emotions out of portfolio decisions. Watch the video below to learn practical rules for rebalancing in retirement. *This video was published on May 29, 2026. Continue reading
Douglas Rissing/iStock via Getty Images Co-authored by Kody's Dividends Corporate debt issuance in the United States continues to perform strongly. During the COVID era, when interest rates were near rock bottom, almost every company that had the ability to refinance its debt did so. It made sense. Debt was extremely cheap, and liquidity was plentiful. This led to many companies seeing a reduction...
Douglas Rissing/iStock via Getty Images Co-authored by Kody's Dividends Corporate debt issuance in the United States continues to perform strongly. During the COVID era, when interest rates were near rock bottom, almost every company that had the ability to refinance its debt did so. It made sense. Debt was extremely cheap, and liquidity was plentiful. This led to many companies seeing a reduction in their overall interest expense. The downside, however, is that now we're starting to see where many of these companies are having to refinance their debt, and interest rates are significantly higher than they were when they were pegged near 0%. This is leading some companies to have to refinance at prices that are otherwise potentially unattractive to them. Corporate debt issuance in 2025 was up 17% compared to 2024 . It's expected that debt issuance in 2026 will be even higher than it was in 2025, potentially reaching levels not seen since 2021. This massive increase in corporate debt issuance, however, is a financial windfall for the companies that evaluate the creditworthiness of the issuing companies as well as assistance in the issuance itself. Today, I want to stop and consider for a moment one company that's pivotal in the credit rating space. Let's dive in! Riding the Wave of Debt Refinancing and Private Credit Moody’s Q1 2026 Earnings Presentation When we last covered Moody’s Corporation ( MCO ) with a Buy rating in April , we liked that it essentially was a global duopoly alongside S&P Global ( SPGI ). We appreciated that its Moody’s Investors Service, or MIS segment, was basically a tollbooth for global corporate debt issuances. Companies either pay a rating agency like Moody’s or S&P for a credit rating, or they simply can’t refinance existing debt or issue new debt. In other words, the necessity of capital flow makes Moody’s as essential to corporations as air is to human existence. We also thought that the company’s Moody’s Analytics, or MA, segment had cl...
NYCstock/iStock Editorial via Getty Images Introduction Soccer fans will recognize my photo choice as where the 2026 FIFA World Cup final will take place. Whether stadium naming rights help sell insurance would be an article in and of itself! When looking for insurance company preferreds, MetLife, Inc. ( MET ) was one of the few large U.S.-centered life and health ones with tradable ones available...
NYCstock/iStock Editorial via Getty Images Introduction Soccer fans will recognize my photo choice as where the 2026 FIFA World Cup final will take place. Whether stadium naming rights help sell insurance would be an article in and of itself! When looking for insurance company preferreds, MetLife, Inc. ( MET ) was one of the few large U.S.-centered life and health ones with tradable ones available. This article updates my last review done in late 2025 and covers all three available. MetLife has three preferred stocks to choose from, those being: MetLife, Floating Rate Non-Cumulative Preferred Stock, Series A ( MET.PR.A ). MetLife, 5.625% Depositary Shares Non-Cumulative Preferred Stock Series E ( MET.PR.E ). MetLife, 4.75% Depositary Shares Non-Cumulative Preferred Stock, Series F ( MET.PR.F ). They also have a fourth, the MetLife 5.25% Fixed-to-Floating Rate Non-Cumulative Preferred Stock Series C, which isn’t covered as it has a $1000 par value and doesn’t trade on an exchange. They last called an issue in 2015. While still in the financial arena of issuers, insurance companies offer a different risk profile than banks overall, and versus regional ones even more so, thus making their preferred stocks a means of diversifying a portfolio’s risk. The potential poor interest rate environment has me rating both the Series E and Series F as Holds. Series A gets a sell rating as its yield badly trails the other two preferreds. MetLife review My preferred stock analysis always starts by gauging the strength of the issuer, starting with the Seeking Alpha description of the issuer (edited). MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates in six segments: Group Benefits; Retirement and Income Solutions; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, paid family and medical le...
Kaliel/iStock via Getty Images Microchip Technology Incorporated ( MCHP ) has gained substantial momentum in the market as the new growth cycle begins to emerge. With two consecutive quarters of year-over-year growth driven by the completion of customer inventory destocking, MCHP should be well-positioned to realize margin-accretive growth over the coming years driven by multiple megatrends across...
Kaliel/iStock via Getty Images Microchip Technology Incorporated ( MCHP ) has gained substantial momentum in the market as the new growth cycle begins to emerge. With two consecutive quarters of year-over-year growth driven by the completion of customer inventory destocking, MCHP should be well-positioned to realize margin-accretive growth over the coming years driven by multiple megatrends across data center development, aerospace & defense and space investments, and increased content per vehicle in automotive. With strengthening market dynamics setting the stage for substantial top-line growth over the coming years, I am recommending MCHP with a Strong Buy rating with a price target of $145/share at 28.52x eFY28 EV/aEBITDA. You can review my previous coverage of MCHP here . Microchip Technology Incorporated Operational Update Corporate Filings MCHP is realizing durable growth across its major end markets, including data centers, industrials, and aerospace & defense, resulting in upbeat double-digit growth across all segments. Growth, in part, is the result of greater content-per-system and long-duration product roadmaps, creating an ideal market environment for the company. The data center market should provide durable growth over the coming years, driven by the growing footprint paired with the transition to AI inferencing and agentic AI. Thematically, AI applications will require higher storage capacity with more output being stored for use and continuous model training efforts. Networking chips are also positioned for growth with 6 design wins for its Gen 6 PCIe data center switch, designed with scale-up & out capabilities for large-scale deployments. Accordingly, the Gen 6 switch is expected to begin ramping up in eq1’27 with production capacity reaching the market throughout eFY27. Expanding in this market, MCHP has introduced XpressConnect PCIe 6.0 and CXL 3.1 retimers to support high-bandwidth architecture, enabling memory expansions and improved performanc...
Getty Images By Mike Larson Today is the big day! The day SpaceX ( SPCX ) will start trading after its $75 billion Initial Public Offering. But no matter how intense the action gets for short-term traders here, long-term investors ultimately care about returns over time. So… should you buy? That’s where the MoneyShow Chart of the Day comes into play. Based on data compiled by longtime IPO expert J...
Getty Images By Mike Larson Today is the big day! The day SpaceX ( SPCX ) will start trading after its $75 billion Initial Public Offering. But no matter how intense the action gets for short-term traders here, long-term investors ultimately care about returns over time. So… should you buy? That’s where the MoneyShow Chart of the Day comes into play. Based on data compiled by longtime IPO expert Jay Ritter at the University of Florida, it makes one thing clear . Unprofitable companies can have stellar debuts… but it’s the ones that make money which typically deliver better returns over time. After Today, Where Will SpaceX Go? Source: Yahoo Finance Specifically, money losers rise 26.5% on average on IPO day. That compares to 13.3% for money makers. But over a three-year horizon, money losers historically generate a 0.5% loss for investors. Money makers deliver average gains of 33.6%. Where does SpaceX fit in? It is losing money . That includes $4.3 billion in red ink during the first quarter of this year – and $4.9 billion for calendar 2025. Heavy capital expenditure bills are weighing on its results, even as Q1 revenue climbed 15.4% year-over-year. But that didn’t stop retail investors from reportedly asking for more than $100 billion in stock – or prevent institutions from vying for multi-billion-dollar slugs of shares. If all goes as expected, SpaceX will debut with a market capitalization of $1.8 trillion. The deal’s 23 banks will pocket hundreds of millions of dollars in fees. And the world may have its first trillionaire in CEO Elon Musk. All I can say is… buckle up! It’s going to be a big day for SpaceX traders. Whether it’s a big couple of years for SpaceX investors remains to be seen. Editor's Note: The summary bullets for this article were chosen by Seeking Alpha editors. Originally published on MoneyShow.com
Had been calls for Nations League tie to be boycotted FAI agree to move contest away from Aviva Stadium The Republic of Ireland are to play their upcoming Nations League game against Israel at a neutral venue behind closed doors following protests by players and fans over the death toll of Palestinian civilians during the war in Gaza. Ireland had been set to host Israel at the Aviva Stadium on 4 O...
Had been calls for Nations League tie to be boycotted FAI agree to move contest away from Aviva Stadium The Republic of Ireland are to play their upcoming Nations League game against Israel at a neutral venue behind closed doors following protests by players and fans over the death toll of Palestinian civilians during the war in Gaza. Ireland had been set to host Israel at the Aviva Stadium on 4 October, while a 27 September fixture designated as an Israel home match is also expected to be staged at a neutral venue. But Irish footballers, fans and celebrities launched a campaign calling for a boycott of the game. Continue reading...
Klaviyo (NYSE: KVYO) is under pressure amid concerns about slowing growth, but the business still shows strong revenue growth, improving profitability, and a broader artificial intelligence-powered platform strategy. The stock's decline creates a real investor dilemma: is this a warning sign, or a misunderstood growth story hiding in plain sight? Stock prices used were the market prices of June 2,...
Klaviyo (NYSE: KVYO) is under pressure amid concerns about slowing growth, but the business still shows strong revenue growth, improving profitability, and a broader artificial intelligence-powered platform strategy. The stock's decline creates a real investor dilemma: is this a warning sign, or a misunderstood growth story hiding in plain sight? Stock prices used were the market prices of June 2, 2026. The video was published on June 11, 2026. Continue reading
Lloyds (LYG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Lloyds (LYG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
utah778/iStock via Getty Images Objective Current income and capital preservation Use for High-quality income opportunities Morningstar category Corporate Bond Click to enlarge Highlights U.S. investment-grade corporate bonds generally declined in the first quarter. The fund underperformed its benchmark, the Bloomberg U.S. Corporate Bond Index. Sector allocation and yield curve positioning weighed...
utah778/iStock via Getty Images Objective Current income and capital preservation Use for High-quality income opportunities Morningstar category Corporate Bond Click to enlarge Highlights U.S. investment-grade corporate bonds generally declined in the first quarter. The fund underperformed its benchmark, the Bloomberg U.S. Corporate Bond Index. Sector allocation and yield curve positioning weighed on performance while individual security selection produced mixed results. Market review and outlook U.S. investment-grade corporate bonds generally declined in a volatile Q1. Bonds rallied during the first two months of the quarter amid mixed economic data and a flight to quality. In March, however, bond yields soared and prices fell in response to escalating conflict in the Middle East. Prices for energy and other commodities spiked higher, stoking concerns about rising inflation. Although the U.S. Federal Reserve (Fed) held short-term interest rates steady throughout the quarter, geopolitical uncertainty led to dramatic changes in expectations for Fed interest rate policy going forward. Instead of anticipating one or two interest rate cuts later in 2026, investors took that off the table and began pricing in an interest rate increase before year-end. For the quarter, bond yields moved higher across the board, reflecting the increased inflationary concerns. Investment-grade corporate bonds underperformed the broader bond market as risk-off market sentiment took hold in the latter part of the quarter. Contributors and detractors The fund underperformed its benchmark in the first quarter, primarily due to sector allocation. An overweight position in the financials sector and an underweight position in the industrials sector detracted the most. Yield curve positioning also weighed on performance versus the index, due largely to an overweight position in the intermediate maturity sector and an underweight position at the long end of the yield curve. Individual security selec...
核心要点 CNBC 记者阿尔琼・卡尔帕尔做客《科技资讯》播客栏目，专访Mistral AI 公司创始人亚瑟・门施，围绕智能体 AI 发展前景、芯片自研、全球人工智能行业现状展开深度对话。 门施首次对外披露，这家法国大模型企业正规划自研专属 AI 芯片。 门施表示：“目前企业端 AI 落地仍存在大量阻滞，这也意味着行业还有巨大价值挖掘空间。” 2023 年 6 月我身在巴黎，当时听闻一则消息：一家仅...
核心要点 CNBC 记者阿尔琼・卡尔帕尔做客《科技资讯》播客栏目，专访Mistral AI 公司创始人亚瑟・门施，围绕智能体 AI 发展前景、芯片自研、全球人工智能行业现状展开深度对话。 门施首次对外披露，这家法国大模型企业正规划自研专属 AI 芯片。 门施表示：“目前企业端 AI 落地仍存在大量阻滞，这也意味着行业还有巨大价值挖掘空间。” 2023 年 6 月我身在巴黎，当时听闻一则消息：一家仅成立四周的初创企业Mistral AI 完成超 1 亿美元融资。彼时这家公司没有成型产品、未开展任何市场宣传，外界对其团队背景也知之甚少。在之后的数月里，我们逐步了解到公司首席执行官亚瑟・门施、核心团队以及他们的远大愿景。 这家最初专注大模型研发的企业，如今目标清晰：打造欧洲本土顶尖 AI 实验室，对标美国 OpenAI、Anthropic 两大前沿 AI 巨头。Mistral正在自建数据中心，全力推动人工智能技术落地各行各业的企业场景。 门施在最新一期《科技资讯》播客访谈中表示：“欧洲已经开始将人工智能视作战略核心资产。” 本次对话内容覆盖面极广，从智能体 AI 的未来走向，到芯片研发布局，再到他对当下 AI 市场格局的完整判断。 近期大家应该频繁看到 “智能体” 或是 “智能体 AI” 这类词汇。其核心概念是一套可自主代人完成长期复杂任务的人工智能系统，相当于高阶数字助手。代码开发是智能体 AI 落地最快的赛道，Anthropic 的 Claude Code、OpenAI 的代码模型 Codex 等产品均收获广泛市场认可。Mistral自研核心智能体产品名为 Vibe，整合了自家对话大模型与代码开发工具。 全面布局智能体 AI 或将重塑企业组织架构。门施提出，企业需要梳理全业务流程，区分可自动化环节与人必须参与管控的环节。他认为，企业应当思考 “如何围绕 AI 系统，重新统筹流程中所有岗位人员的协作模式”。 Mistral的布局不止局限软件层面。公司自建数据中心为自研大模型与 AI 应用提供算力支撑，背后逻辑是掌控完整技术栈，从底层大模型到运行所需算力实现自主可控。 目前这批自建数据中心主要搭载英伟达芯片。但本次访谈中爆出重磅消息：门施首次对外透露，Mistral正在探索自研 AI 芯片， 谷歌 、 亚马逊 等美国大型云服务商早已采取同类战略。 总体而言，门施判断人工智...
Getty Images Investment thesis Caris Life Sciences ( CAI ) combines 79% revenue growth in Q1 2026, positive free cash flow and gross margins above 65%. Beyond its diagnostic tests, the company has built a genomic database of more than one million profiled cases that may support future products such as Caris Detect, creating a potential competitive advantage that the market may be overlooking. I be...
Getty Images Investment thesis Caris Life Sciences ( CAI ) combines 79% revenue growth in Q1 2026, positive free cash flow and gross margins above 65%. Beyond its diagnostic tests, the company has built a genomic database of more than one million profiled cases that may support future products such as Caris Detect, creating a potential competitive advantage that the market may be overlooking. I believe the stock's valuation is more than compelling, since at 5x EV/Sales, Caris is undervalued relative to peers despite higher growth and profitability, leading me to assign a Buy rating. From diagnostic tests to data assets In oncology, doctors use genetic information to better understand a patient's cancer and select the most appropriate treatments. Caris participates in this market through molecular profiling tests that analyze tumor tissue or blood samples and help oncologists identify the therapies that may be most effective for each patient. What I think makes the company interesting is that Caris doesn't stop once a test is completed. Each test adds to Caris' genomic database, which now contains more than 1 million profiled cases and can be used to generate insights, support new drug development and improve future products. If you read my article about IQVIA ( IQV ), you'll realize how relevant having these huge databases can be for a healthcare provider, so this part of Caris's business seems to me a differentiator worth mentioning. Caris Q1 2026 presentation While the current business is already growing rapidly (79% in Q1 2026 ), I think the larger opportunity may come from Caris Detect, the upcoming blood-based cancer screening test. Unlike Caris' existing products, which are used after a cancer diagnosis has been made, Caris Detect is designed to identify cancer at much earlier stages. That expands the market, as the focus shifts from helping choose treatments to identifying patients before symptoms even appear. What makes this product interesting is that Caris...